Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study

被引：1

作者：

Patel, Krish ^{[1
]}

Vose, Julie M. ^{[2
]}

Nasta, Sunita D. ^{[3
]}

Brown, Jennifer R. ^{[4
,5
]}

Maddocks, Kami J. ^{[6
]}

Woyach, Jennifer A. ^{[6
]}

Shah, Nirav N. ^{[7
]}

Fakhri, Bita ^{[8
]}

Tessoulin, Benoit ^{[9
]}

Ma, Shuo ^{[10
]}

Jagadeesh, Deepa ^{[11
]}

Lech-Maranda, Ewa ^{[12
]}

Coombs, Catherine C. ^{[13
]}

Patel, Manish ^{[14
]}

Rhodes, Joanna M. ^{[15
]}

Ujjani, Chaitra S. ^{[16
]}

Hoffmann, Marc S. ^{[17
]}

Cheah, Chan Y. ^{[18
,19
]}

Munir, Talha ^{[20
]}

Lewis, David ^{[21
]}

Scarfo, Lydia ^{[22
]}

Eyre, Toby A. ^{[23
]}

Alencar, Alvaro J. ^{[24
]}

Cohen, Jonathon B. ^{[25
]}

Zelenetz, Andrew D. ^{[26
]}

Tsai, Donald E. ^{[27
]}

Li, Mei ^{[28
]}

Bian, Faith ^{[28
]}

Abada, Paolo ^{[27
]}

Zinzani, Pier Luigi ^{[29
]}

机构：

[1] Swedish Canc Inst, Seattle, WA USA

[2] Univ Nebraska Med Ctr, Omaha, NE USA

[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[4] Dana Farber Canc Inst, Chron Lymphocyt Leukemia Ctr, Div Med Oncol, Boston, MA 02115 USA

[5] Harvard Med Sch, Boston, MA 02115 USA

[6] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[7] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[8] Stanford Univ, Sch Med, Stanford, CA USA

[9] Univ Hosp, Dept Hematol, Nantes, France

[10] Cleveland Clin, Dept Hematol & Med Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA

[11] Inst Hematol & Transfus Med, Warsaw, Poland

[12] Univ Calif Irvine, Irvine, CA USA

[13] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA

[14] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[15] Fred Hutchinson Canc Ctr, Seattle, WA USA

[16] Univ Kansas, Ctr Canc, Kansas City, KS USA

[17] Linear Clin Res, Nedlands, WA, Australia

[18] Sir Charles Gairdner Hosp, Nedlands, WA, Australia

[19] St James Univ Hosp, Dept Haematol, Leeds, W Yorkshire, England

[20] Univ Hosp Plymouth NHS Trust, Plymouth, Devon, England

[21] Univ Vita Salute San Raffaele, Milan, Italy

[22] IRCCS San Raffaele Sci Inst, Milan, Italy

[23] Oxford Univ Hosp NHS Trust, Dept Clin Haematol, Old Rd, Oxford, England

[24] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami Beach, FL USA

[25] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[26] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[27] Loxo Lilly, Indianapolis, IN USA

[28] Eli Lilly & Co, Indianapolis, IN 46285 USA

[29] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-180048

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：9

共 50 条

[1] Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study
Shah, Nirav N.
Zinzani, Pier Luigi
Wang, Michael L.
Nasta, Sunita D.
Lech-Maranda, Ewa
Ogawa, Yoshiaki
Fakhri, Bita
Kuss, Bryone
Miyashita, Kaname
Patel, Krish
Coombs, Catherine C.
Ma, Shuo
Patel, Manish
Barve, Minal A.
Tessoulin, Benoit
Stathis, Anastasios
Kim, Won Seog
Ennishi, Daisuke
Hashimoto, Daigo
Kojima, Kensuke
Zelenetz, Andrew D.
Cohen, Jonathon B.
Vose, Julie M.
Maddocks, Kami J.
Munir, Talha
Sun, Fangfang
Bian, Faith
Tsai, Donald E.
Abada, Paolo
Cheah, Chan Y.
BLOOD, 2023, 142
[2] Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenstrom Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
Palomba, M. Lia
Patel, Manish R.
Eyre, Toby A.
Jurczak, Wojciech
Lewis, David John
Gastinne, Thomas
Ma, Shuo
Cohen, Jonathon B.
Patel, Krish
Brown, Jennifer R.
Scarfo, Lydia
Munir, Talha
Lech-Maranda, Ewa
Hoffmann, Marc
Ujjani, Chaitra S.
Fakhri, Bita
Wang, Michael L.
Izutsu, Koji
Nagai, Hirokazu
Tam, Constantine S.
Seymour, John F.
Rhodes, Joanna M.
Vose, Julie M.
McKinney, Matthew
Gerson, James N.
Barve, Minal A.
Kuss, Bryone J.
Koh, Youngil
Gao, Wei
Ruppert, Amy S.
Walgren, Richard A.
Tsai, Donald E.
Nair, Binoj
Bao, Katherine
Mato, Anthony R.
Cheah, Chan Y.
BLOOD, 2022, 140
[3] Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
Wierda, William G.
Lewis, David John
Ghia, Paolo
Shah, Nirav N.
Coombs, Catherine C.
Cheah, Chan Y.
Lamanna, Nicole
Rhodes, Joanna M.
Hoffmann, Marc
Ma, Shuo
Eyre, Toby A.
Munir, Talha
Patel, Manish R.
Alencar, Alvaro J.
Tam, Constantine S.
Seymour, John F.
Jurczak, Wojciech
Lech-Maranda, Ewa
Roeker, Lindsey E.
Thompson, Philip A.
Abada, Paolo B.
Wang, Chunxiao
Nair, Binoj
Liu, Hui
Tsai, Donald E.
Mato, Anthony R.
BLOOD, 2022, 140
[4] Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: Results from the phase 1/2 BRUIN study
Rhodes, Joanna
Lewis, David
Ghia, Paolo
Shah, Nirav N.
Coombs, Catherine C.
Cheah, Chan Y.
Woyach, Jennifer
Lamanna, Nicole
Hoffmann, Marc S.
Ma, Shuo
Eyre, Toby A.
Munir, Talha
Patel, Manish R.
Alencar, Alvaro J.
Tam, Constantine S.
Seymour, John F.
Jurczak, Wojciech
Lech-Maranda, Ewa
Roeker, Lindsey E.
Thompson, Philip A.
Abada, Paolo B.
Wang, Chunxiao
Nair, Binoj
Liu, Hui
Tsai, Donald E.
Mato, Anthony R.
Wierda, William G.
CANCER RESEARCH, 2023, 83 (08)
[5] Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated Mantle Cell Lymphoma: Updated Results From The Phase 1/2 BRUIN Study
Wang, Michael
Shah, Nirav
Alencar, Alvaro
Gerson, James
Patel, Manish
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan
Lewis, Katharine
Fenske, Timothy
Coombs, Catherine
Flinn, Ian
Lewis, David
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer
Pagel, John
Lamanna, Nicole
Cohen, Johnathon
Barve, Minal
Ghia, Paolo
Eyre, Toby
Zinzani, Pier Luigi
Ujjani, Chaitra
Koh, Youngil
Izutsu, Koji
Lech-Maranda, Ewa
Tam, Constantine
Sundaram, Suchitra
Yin, Ming
Nair, Binoj
Tsai, Donald
Balbas, Minna
Mato, Anthony
Cheah, Chan
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 101 - 104
[6] Pirtobrutinib, a highly selective, non-covalent BTK inhibitor in Richter transformation: Results from the BRUIN study
Lewis, David John
Wierda, William G.
Ghia, Paolo
Shah, Nirav N.
Coombs, Catherine C.
Cheah, Chan Y.
Lamanna, Nicole
Rhodes, Joanna M.
Hoffmann, Marc S.
Ma, Shuo
Eyre, Toby A.
Munir, Talha
Patel, Manish R.
Alencar, Alvaro J.
Tam, Constantine S.
Seymour, John F.
Jurczak, Wojciech
Lech-Maranda, Ewa
Roeker, Lindsey E.
Thompson, Philip A.
Abada, Paolo B.
Wang, Chunxiao
Nair, Binoj
Liu, Hui
Tsai, Donald E.
Mato, Anthony R.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 107 - 108
[7] Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study
Coombs, Catherine C.
Pagel, John M.
Shah, Nirav N.
Lamanna, Nicole
Munir, Talha
Lech-Maranda, Ewa
Eyre, Toby A.
Woyach, Jennifer A.
Wierda, William G.
Cheah, Chan Y.
Cohen, Jonathon B.
Roeker, Lindsey E.
Patel, Manish R.
Fakhri, Bita
Barve, Minal A.
Tam, Constantine S.
Lewis, David
Gerson, James N.
Alencar, Alvaro
Ujjani, Chaitra
Flinn, Ian
Sundaram, Suchitra
Ma, Shuo
Jagadeesh, Deepa
Rhodes, Joanna
Taylor, Justin
Abdel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen J.
Wang, Denise
Nair, Binoj
Zhu, Edward
Tsai, Donald E.
Davids, Matthew S.
Brown, Jennifer R.
Jurczak, Wojciech
Mato, Anthony R.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S268 - S269
[8] Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study
Mato, Anthony
Pagel, John
Coombs, Catherine
Shah, Nirav
Lamanna, Nicole
Munir, Talha
Lech-Maranda, Ewa
Eyre, Toby
Woyach, Jennifer
Wierda, William
Cheah, Chan
Cohen, Johnathan
Roeker, Lindsey
Patel, Manish
Fakhri, Bita
Barve, Minal
Tam, Constantine
Lewis, David
Gerson, James
Alencar, Alvaro
Ujjani, Chaitra
Flinn, Ian
Sundaram, Suchitra
Ma, Shuo
Jagadeesh, Deepa
Rhodes, Joanna
Taylor, Justin
Abdel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen
Wang, Denise
Nair, Binoj
Zhu, Edward
Tsai, Donald
Davids, Matthew
Brown, Jennifer
Jurczak, Wojciech
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 97 - 101
[9] Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed/refractory Waldenstrom macroglobulinemia
Lewis, David John
Palomba, M. Lia
Patel, Manish R.
Eyre, Toby A.
Jurczak, Wojciech
Gastinne, Thomas
Ma, Shuo
Cohen, Jonathon B.
Patel, Krish
Brown, Jennifer R.
Scarfo, Lydia
Munir, Talha
Lech-Maranda, Ewa
Hoffmann, Marc S.
Ujjani, Chaitra S.
Fakhri, Bita
Wang, Michael
Izutsu, Koji
Nagai, Hirokazu
Tam, Constantine S.
Seymour, John F.
Rhodes, Joanna M.
Vose, Julie
McKinney, Matthew
Gerson, James N.
Barve, Minal A.
Kuss, Bryone
Koh, Youngil
Gao, Wei
Ruppert, Amy S.
Walgren, Richard A.
Tsai, Donald E.
Nair, Binoj
Bao, Katherine
Mato, Anthony R.
Cheah, Chan Y.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 109 - 110
[10] Pirtobrutinib, A Next Generation, Highly Selective, Non-covalent BTK Inhibitor In Previously Treated Mantle Cell Lymphoma: Updated Results From The Phase 1/2 BRUIN Study
Shah, Nirav N.
Alencar, Alvaro J.
Gerson, James N.
Patel, Manish R.
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan
Lewis, Katharine
Fenske, Timothy
Coombs, Catherine C.
Flinn, Ian
Lewis, David
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer
Pagel, John M.
Lamanna, Nicole
Cohen, Johnathon B.
Barve, Minal A.
Ghia, Paolo
Eyre, Toby A.
Mato, Anthony R.
Cheah, Chan Y.
Wang, Michael L.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 170 - 171

← 1 2 3 4 5 →